• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Moderna

FDA concludes Pfizer-BioNTech vaccine likely safe and effective in kids under 5

June 13, 2022 By Brian Buntz

In the U.S., COVID-19 vaccines are widely available to all age groups apart from children under the age of five. However, that could change this month now that FDA has signaled that three doses of the Pfizer-BioNTech (NYSE:PFE/Nasdaq BNTX) COVID-19 vaccine are likely effective against COVID-19 in an analysis ahead of a June 15 Vaccines […]

Filed Under: Blog, Featured, Pharmaceutical Tagged With: BioNTech, COVID-19 vaccine, Moderna, Pfizer

Moderna’s first bivalent COVID-19 vaccine booster candidate shows promise

May 19, 2022 By Brian Buntz

Moderna’s (NYSE:MRNA) bivalent booster COVID-19 vaccine candidate, mRNA-1273.211, bested its first-generation mRNA-1273 vaccine in a Phase 2/3 study. The study compared the neutralizing antibody levels generated from both vaccine boosters. The mRNA-1273.211 vaccine booster candidate offered superior performance against all variants of concern, including omicron. Get the full story from our sister site, Drug Discovery […]

Filed Under: Clinical Trials, Featured, Pharmaceutical Tagged With: COVID-19 vaccine candidate, Moderna, mRNA-1273, mRNA-1273.211, vaccine

Moderna’s new CFO leaves after former employer discloses investigation

May 11, 2022 By Brian Buntz

Moderna (Nasdaq:MRNA) CFO Jorge Gomez is gone from his new job effective immediately, the COVID-19 vaccine maker said today. Cambridge, Massachusetts–based Moderna said the departure comes after Gomez’s former employer, Dentsply Sirona (Nasdaq: XRAY), announced an “ongoing internal investigation into certain matters, including financial reporting,” Moderna said in a news release. Get the full story […]

Filed Under: Blog, Featured, Pharmaceutical Tagged With: Dentsply Sirona, Jorge Gomez, Moderna

FDA signals careful approach in authorizing COVID-19 vaccines in young children

May 2, 2022 By Brian Buntz

FDA is planning a series of virtual meetings of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) throughout June. In the meetings, the advisory committee will discuss authorizing the COVID-19 vaccine from Novavax (Nasdaq:NVAX) and authorizing the use of the vaccines from Moderna (Nasdaq: MRNA) and Pfizer-BioNTech (NYSE:PFE; Nasdaq:BNTX) in children aged 6 months […]

Filed Under: Featured, Pharmaceutical Tagged With: BioNTech, COVID-19 vaccines, FDA, Moderna, Novavax, NVX‑CoV2373, Pfizer, Vaccines and Related Biological Products Advisory Committee, VRBPAC

Moderna seeks authorization for COVID-19 vaccine in children as young as 6 months old

April 28, 2022 By Brian Buntz

While a portion of the public is now eligible to receive a second booster dose of COVID-19 vaccine, the FDA has not yet authorized a vaccine for children aged 6 months to 5 years old. Moderna (Nasdaq:MRNA) is vying to be the first. The company announced today that it is filing a request for emergency […]

Filed Under: Blog, Featured, Pharmaceutical Tagged With: children, COVID-19 vaccine, Moderna, mRNA-1273

Moderna says bivalent COVID-19 boosters could offer more robust protection against variants

April 19, 2022 By Brian Buntz

Moderna (Nasdaq:MRNA) announced that its first bivalent booster vaccine candidate, mRNA-1273.211, offered superior protection against SARS-CoV-2 variants of concern compared with its first-gen mRNA-1273 vaccine. A 50-µg booster of the mRNA-1273.211 vaccine offered protection against the beta, delta and omicron variants for six months and appeared to provide similar tolerability to the FDA-approved mRNA-1273 vaccine. […]

Filed Under: Blog, Featured, Pharmaceutical Tagged With: coronavirus, COVID-19, Moderna, mRNA-1273.211, SARS-CoV-2, variants of concern

Dentsply CFO Jorge Gomez leaves to assume same role at Moderna

April 11, 2022 By Sean Whooley

Moderna (Nasdaq:MRNA) announced today that it appointed Jorge Gomez as its new chief financial officer. Gomez resigned as CFO of Dentsply Sirona (Nasdaq:XRAY), effective May 6, to assume the same role at Cambridge, Massachusetts-based Moderna. He will join effective May 9. Dentsply Sirona said in a news release that it is initiating a search process […]

Filed Under: Business/Financial News, Dental, Featured, News Well, Pharmaceutical Tagged With: Dentsply Sirona, Moderna, Personnel Moves

Moderna says its mRNA Access program could help with the next pandemic

March 17, 2022 By Brian Buntz

Moderna’s mRNA Access program (Nasdaq: MRNA) enables researchers to use its mRNA technology platform for research projects related to emerging and neglected infectious diseases. “It takes a community of scientists and disease experts to develop novel vaccines to tackle our greatest public health threats,” said Hamilton Bennett, Moderna’s senior director, vaccine access and partnerships. “mRNA Access was […]

Filed Under: Blog, Featured, News Well, Pharmaceutical Tagged With: infectious diseases, Moderna, mRNA, mRNA vaccines

NIH to launch clinical trial of three mRNA HIV vaccines

March 14, 2022 By Brian Buntz

The National Institute of Allergy and Infectious Diseases (NIAID) has announced a Phase 1 clinical study of HIV vaccines using mRNA sequences. The study will test the safety and immunogenicity of three investigational HIV mRNA vaccines known as BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA and BG505 MD39.3 gp151 CD4KO mRNA. Get the full story […]

Filed Under: Blog, Health Information Technology, Pharmaceutical Tagged With: HIV, Moderna, National Institute of Allergy and Infectious Diseases, NIAID, NIH

NIH to study allergic reactions to COVID-19 mRNA vaccine

March 9, 2022 By Sean Whooley

Researchers from the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) are conducting a clinical trial on allergic reactions to mRNA-based COVID-19 vaccines. The single-site trial will enroll up to 100 people between 16 and 69 years old who had an allergic reaction to a first dose of COVID-19 mRNA vaccines. NIAID seeks participants […]

Filed Under: Clinical Trials, Featured, Pharmaceutical Tagged With: BioNTech, coronavirus, COVID-19, Moderna, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Pfizer

Countries in need will have access to Moderna COVID-19 vaccine tech

March 8, 2022 By Sean Whooley

Moderna (Nasdaq:MRNA) announced four new initiatives within a global public health strategy for advancing mRNA vaccines. Cambridge, Massachusetts-based Moderna plans to expand its global public health portfolio, accelerate research in an effort to advance additional vaccines, expand its patent pledge to never enforce COVID-19 patents in the Gavi COVAX AMC for 92 low- and middle-income […]

Filed Under: Business/Financial News, Contract Manufacturing, Featured, Pharmaceutical Tagged With: coronavirus, COVID-19, Moderna

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 7
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy